IP Library Granted Patent US 7,659,260
Granted Patent B2
US 7,659,260 · App. 11/035,748 · Granted Feb 9, 2010

Tamponade compositions and methods for retinal repair

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,659,260
App. No.
11/035,748
Granted
Feb 9, 2010
Kind
B2
Abstract

Described herein are methods of repairing retinal tissue using resorbable tamponade compositions that are heavier than aqueous humor and contain one or more glysosaminoglycans.

Claims (12)

1. A method of treating a break in retinal tissue in a subject, the method comprising:

removing the vitreous humor from the vitreous cavity of the subject's eye; and

administering into the vitreous cavity an amount of a tamponade composition sufficient to cover the retinal detachment or the macular hole, wherein the tamponade composition comprising:

(a) a non-toxic, resorbable liquid that is denser than aqueous humor, wherein said liquid is deuterium-containing heavy water, and

(b) at least one glycosaminoglycan selected from the group consisting of hyaluronic acid, chondroitin sulfate, keratan sulfate, keratan sulfate II, heparan sulfate, and dermatan sulfate and a non-toxic, resorbable liquid that is denser than aqueous humor.

2. The method of claim 1 , wherein the tamponade composition comprises about 0.05 mg of the glycosaminoglycan per milliliter of the composition.

3. The method of claim 2 , wherein the glycosaminoglycan is hyaluronic acid.

4. The method of claim 3 , wherein the tamponade composition further comprises about 0.05 mg of chondroitin sulfate per milliliter of the composition.

5. The method of claim 1 , wherein the tamponade composition comprises from about 0.9 mg to 5 mg of the glycosaminoglycan per milliliter of the composition.

6. The method of claim 5 , wherein the glycosaminoglycan is hyaluronic acid.

7. The method of claim 6 , wherein the tamponade composition further comprises about 0.05 mg of chondroitin sulfate per milliliter of the composition.

8. The method of claim 1 , wherein the subject has (i) a superior retinal detachment and (ii) an inferior retinal detachment or a macular hole, and the method further comprises administering a gaseous tamponade agent to the vitreous cavity of the eye.

Continuity (1)
Related Publication 20060159771A1 · Jul 20, 2006